These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

627 related articles for article (PubMed ID: 29675844)

  • 41. Bioactivation antioxidant and transglycating properties of N-acetylcarnosine autoinduction prodrug of a dipeptide L-carnosine in mucoadhesive drug delivery eye-drop formulation: powerful eye health application technique and therapeutic platform.
    Babizhayev MA
    Drug Test Anal; 2012 Jun; 4(6):468-85. PubMed ID: 21416634
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Feasibility of lipid nanoparticles for ocular delivery of anti-inflammatory drugs.
    Souto EB; Doktorovova S; Gonzalez-Mira E; Egea MA; Garcia ML
    Curr Eye Res; 2010 Jul; 35(7):537-52. PubMed ID: 20597640
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Aqueous eye drops containing drug/cyclodextrin nanoparticles deliver therapeutic drug concentrations to both anterior and posterior segment.
    Loftsson T; Stefánsson E
    Acta Ophthalmol; 2022 Feb; 100(1):7-25. PubMed ID: 33876553
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Anterior eye segment drug delivery systems: current treatments and future challenges.
    Molokhia SA; Thomas SC; Garff KJ; Mandell KJ; Wirostko BM
    J Ocul Pharmacol Ther; 2013 Mar; 29(2):92-105. PubMed ID: 23485091
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safety evaluation of ocular drug delivery formulations: techniques and practical considerations.
    Short BG
    Toxicol Pathol; 2008 Jan; 36(1):49-62. PubMed ID: 18337221
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nanotechnology based drug delivery systems for the treatment of anterior segment eye diseases.
    Onugwu AL; Nwagwu CS; Onugwu OS; Echezona AC; Agbo CP; Ihim SA; Emeh P; Nnamani PO; Attama AA; Khutoryanskiy VV
    J Control Release; 2023 Feb; 354():465-488. PubMed ID: 36642250
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Recent progress in ocular drug delivery for posterior segment disease: emphasis on transscleral iontophoresis.
    Myles ME; Neumann DM; Hill JM
    Adv Drug Deliv Rev; 2005 Dec; 57(14):2063-79. PubMed ID: 16310884
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ocular Drug Delivery: Present Innovations and Future Challenges.
    Gote V; Sikder S; Sicotte J; Pal D
    J Pharmacol Exp Ther; 2019 Sep; 370(3):602-624. PubMed ID: 31072813
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Solid lipid nanoparticles as promising tool for intraocular tobramycin delivery: Pharmacokinetic studies on rabbits.
    Chetoni P; Burgalassi S; Monti D; Tampucci S; Tullio V; Cuffini AM; Muntoni E; Spagnolo R; Zara GP; Cavalli R
    Eur J Pharm Biopharm; 2016 Dec; 109():214-223. PubMed ID: 27789355
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Nanoparticles for drug delivery to the anterior segment of the eye.
    Janagam DR; Wu L; Lowe TL
    Adv Drug Deliv Rev; 2017 Dec; 122():31-64. PubMed ID: 28392306
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Drug delivery to the eye: what benefits do nanocarriers offer?
    Joseph RR; Venkatraman SS
    Nanomedicine (Lond); 2017 Mar; 12(6):683-702. PubMed ID: 28186436
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Recent advance of nanoparticle-based topical drug delivery to the posterior segment of the eye.
    Wang Y; Xu X; Gu Y; Cheng Y; Cao F
    Expert Opin Drug Deliv; 2018 Jul; 15(7):687-701. PubMed ID: 29985660
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Topical and systemic drug delivery to the posterior segments.
    Hughes PM; Olejnik O; Chang-Lin JE; Wilson CG
    Adv Drug Deliv Rev; 2005 Dec; 57(14):2010-32. PubMed ID: 16289435
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Nanotechnology for Topical Drug Delivery to the Anterior Segment of the Eye.
    Vaneev A; Tikhomirova V; Chesnokova N; Popova E; Beznos O; Kost O; Klyachko N
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830247
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In vitro and in vivo evaluation of in situ gelling systems for sustained topical ophthalmic delivery: state of the art and beyond.
    Destruel PL; Zeng N; Maury M; Mignet N; Boudy V
    Drug Discov Today; 2017 Apr; 22(4):638-651. PubMed ID: 28017837
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Current and future ophthalmic drug delivery systems. A shift to the posterior segment.
    Del Amo EM; Urtti A
    Drug Discov Today; 2008 Feb; 13(3-4):135-43. PubMed ID: 18275911
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Light-responsive in situ forming injectable implants for effective drug delivery to the posterior segment of the eye.
    Bisht R; Jaiswal JK; Chen YS; Jin J; Rupenthal ID
    Expert Opin Drug Deliv; 2016 Jul; 13(7):953-62. PubMed ID: 26967153
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Recent advances in topical nano drug-delivery systems for the anterior ocular segment.
    Lakhani P; Patil A; Majumdar S
    Ther Deliv; 2018 Feb; 9(2):137-153. PubMed ID: 29325511
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Novel drug delivery systems for ocular therapy: With special reference to liposomal ocular delivery.
    Bhattacharjee A; Das PJ; Adhikari P; Marbaniang D; Pal P; Ray S; Mazumder B
    Eur J Ophthalmol; 2019 Jan; 29(1):113-126. PubMed ID: 29756507
    [TBL] [Abstract][Full Text] [Related]  

  • 60. ISOPT
    Kompella UB; Domb A; Urtti A; Jayagopal A; Wilson CG; Tang-Liu D
    J Ocul Pharmacol Ther; 2019 Oct; 35(8):457-465. PubMed ID: 31259643
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.